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Abstract: Monocytes migrate through the blood to the peripheral tissues, where they can develop into dendritic cells 
(DC) and macrophages. Studies on the phenotype of peripheral blood monocytes in rheumatic diseases revealed changes 
in the number of CD16+ monocytes and in the adhesive, chemotactic, antigen presenting and inflammatory properties of 
the cells. However, these studies often resulted in fragmented and inconsistent data and are hampered by the heterogeneity 
and overlap of the rheumatic diseases.  
By microarray analysis, changes in gene expression-profiles are detectable and subsequent correlation of the data reveals 
functional pathways forming a “gene expression signature”. Determination of monocyte gene expression signatures in pa-
tient groups with rheumatic diseases has resulted in the detection of an Interferon (IFN) Type I induced signature in sub-
groups of patients with rheumatoid arthritis, Sjögren’s Syndrome, systemic sclerosis and systemic lupus erythematosus. 
We assume that such profiling, which is robust, will lead to the development of better classification criteria and an insight 
into at least one functional pathogenic pathway leading to disease, i.e. the one mediated by IFN type 1. 
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MONOCYTES AND THE MONONUCLEAR PHAGO-
CYTE SYSTEM (MPS) 
 Monocytes are part of the Mononuclear Phagocyte Sys-
tem (MPS) system. Cells of the MPS system are thought to 
originate from pro-monocytes in the bone marrow and to 
migrate as monocytes through the blood to the peripheral 
tissues, where they replenish the pool of tissue and inflam-
matory macrophages. In addition, monocytes can function as 
precursors of the so-called monocyte-derived dendritic cells 
(DC). DC and macrophages are present in virtually all tis-
sues and play an important role in tissue homeostasis 
(growth and function of parenchymal cells), the removal of 
debris and the regulation of the immune response. In addi-
tion to the blood monocyte as a precursor for tissue macro-
phages and DC, evidence is accumulating that in many tis-
sues monocyte-like precursors for macrophages and DC are 
present locally. Under steady state conditions, DC and tissue 
macrophages are in a tolerogenic state, interacting with T 
cells in such a way that the induction of autoimmune re-
sponses is prevented by a preferential generation of tolero-
genic regulator T cells. Under inflammatory conditions DC 
and macrophages can initiate effector T cells responses re-
sulting in the induction of specific immunity and the ultimate 
elimination of pathogens. Monocytes can be divided into 
different subsets according to phenotype and function [1]. In 
humans, two populations have been distinguished based 
upon the expression of CD14 and CD16. The majority of 
monocytes is CD14+ and CD16-, while approximately 10% 
of the monocytes is CD14+ and CD16+. Further phenotypic 
characterization of the monocyte subsets revealed that the  
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CD16+ monocytes have a high expression of the CX3CR1 
receptor and low levels of CCR2 and CD62L [2]. This latter 
population is considered to be relatively mature in compari-
son to CD14+CD16- monocytes [3,4]. The immature CD16- 
population is considered to be the population from which the 
inflammatory monocytes are recruited during inflammation, 
while the mature population would be precursors of the 
steady state tissue macrophages and DC. Recently, it has 
been proposed that the CD16+ monocyte subset can be fur-
ther sub-divided into two dinstinct functional subsets, CD14 
(high)CD16+ and CD14(dim)CD16+ [5,6]. Future studies 
will no doubt reveal the presence of more functionally dis-
tinct subsets and their contribution to inflammation and auto-
immunity.  
 In summary, the family of monocytes, macrophages and 
DC is a large family of functionally and developmentally 
related cells that are essential for the induction of tolerance 
towards autoantigens (non-dangerous steady state condi-
tions) or the building of effective immune responses to dan-
gerous intruders. Peripheral blood monocytes can act as pre-
cursors for DC and macrophages and offer an opportunity to 
study the MPS system in autoimmune diseases and identify 
abnormalities that contribute to the failure of the immune 
system to preserve a tolerogenic steady state. 
ABBERATIONS OF MONOCYTES IN RHEUMATIC 
DISEASES 
 Animal models for autoimmunity allow the study of the 
earliest steps in the development of the disease. These stud-
ies revealed macrophages and DC to be the first cells accu-
mulating in the target organ, e.g. the synovium in rheumatoid 
arthritis (RA), the islets in Type 1 diabetes (T1D) and the 
salivary glands in Sjögren’s Syndrome (SjS) [7-10]. During 
the development of such autoimmune diseases the accumula-
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tion of monocytes and monocyte-derived cells in target or-
gans is crucial for the induction and perpetuation of the auto-
immune response.  
 In particular we have studied the development of SjS and 
T1D in the Non-Obese Diabetic (NOD) mouse. In the pre-
autoimmune animal (3-7 weeks of age) an accumulation of 
DC occurred in the salivary glands and pancreas before the 
start of any noteworthy T cell infiltration. This observation 
underscores the important role of DC in the pathogenesis of 
the disease. We hypothesized that intrinsic abnormalities in 
dendritic and related cells contribute to the abnormal accu-
mulation of DC in the target organs. Indeed several investi-
gators have reported on an abnormal functioning and traf-
ficking of DC and macrophages in the NOD mouse prior to 
the outbreak of the autoimmune disease [11-16], suggesting 
an incapability of the cells to induce tolerance towards auto-
antigens. Correction of the aberrant function of DC via in-
troduction of corrected DC has been shown to lead to the 
prevention and/or delay of onset of autoimmunity in the 
NOD mouse [17, 18].  
 Considering the important role of DC and macrophages 
in the initiation of autoimmunity and that peripheral blood 
monocytes are important precursors for DC and macro-
phages, peripheral blood monocytes of patients with auto-
immune diseases were studied for phenotypic and functional 
abnormalities.  
 In monocytes of T1D patients a raised production of in-
terleukin
 
(IL)-1, IL-6, superoxide anion, and prostaglandin-
endoperoxide
 
synthase 2 (PTGS2) [19-21], an aberrant gen-
eration of antigen-presenting
 
cells [22, 23] and abnormal 
chemotaxis, adhesion, and migratory
 
potential [24] have 
been described.  
 With regard to rheumatic diseases, studies on the pheno-
type of peripheral blood monocytes revealed several abnor-
malities. An increase in the CD14+CD16+ subset was ob-
served in RA and systemic lupus erythematosus (SLE) pa-
tients [25-27, unpublished results]. However for RA a de-
crease of this population has also been reported [28]. We 
recently described a significant increase in the 
CD14+CD16+ subset in primary SjS (pSjS) [27]. These ma-
ture CD14+CD16+ monocytes displayed a normal expres-
sion of chemokine receptors and adhesion molecules. Using 
an in vitro reverse transmigration assay we demonstrated that 
DC generated from the CD14+CD16+ subset displayed a 
similar phenotype as the DC in pSjS salivary glands. These 
data support a role for CD14+CD16+ monocytes in the 
pathogenesis of pSjS. 
 In addition to shifts in monocyte subpopulations other 
aberrancies in monocytes in rheumatic diseases have been 
reported. In RA an increased expression of Fc receptors and 
an increased adhesion to the extracellular matrix has been 
described [29, 30]. In addition, an activated population of 
CCR5+ monocytes was found in the synovial fluid of RA 
patients indicative for a role of these cells in the pathogene-
sis of RA [31, 32]. The relationship between disease activity 
and an enhanced expression of the Dipeptidyl Peptidase IV 
density on monocytes of RA patients also underscores the 
contribution of abnormally functioning monocytes to the 
disease development [33]. 
 Blocking TNF-alpha has a beneficial effect in a propor-
tion of RA patients. Interestingly, monocytes of RA patients 
have an increased activation of nuclear factor-kappaB 
(NFB) that correlates to peripheral blood TNF-alpha levels 
[34]. Ex vivo treatment with infliximab and etanercept re-
sulted in decreased activation of NFB in monocytes and not 
lymphocytes, further underscoring the important role of 
monocytes in the pathogenesis of RA.  
 In SLE a defective phagocytosis of monocytes and 
macrophages has been implicated in the pathogenesis of this 
systemic autoimmune disease. The envisaged cascade of 
events is thought to be triggered by impaired phagocytosis of 
monocytes/macrophages, resulting in the accumulation of 
apoptotic nuclear debris leading to the triggering of autoim-
mune phenomena towards nuclear antigens, including anti-
nuclear antibodies. Subsequently, immune complexes accu-
mulate resulting in the tissue damage observed in SLE [35]. 
However such a phagocytic clearance deficiency has only 
been observed in a subgroup of patients [35]. Recently the 
theory was expanded to include much broader abnormalities 
in monocytes and macrophages being involved in the basis 
of the disease after observations in SLE animal models [36]. 
Apart from an increased production of inflammatory media-
tors and increased expression of activation induced mole-
cules by monocytes, some SLE patients exhibit monocytes 
that function as highly efficient antigen presenting cells in an 
in vitro mixed lymphocyte reaction [37]. This “DC like” 
behavior of the monocytes, that is absent in healthy control 
cells, is probably caused by the presence of IFN alpha in the 
serum of the patients and might lead to the activation of 
autoreactive T cells. 
 Systemic Sclerosis (SSc), is a rheumatic disease charac-
terized by fibrosis, vascular abnormalities and pulmonary 
hypertension. The etiology and pathogenesis of this disease 
is poorly understood [38]. In the pathogenesis of this gener-
alized autoimmune disease monocytes are also considered to 
play an important role by interacting with endothelial cells 
and fibroblasts via the production of inflammatory factors. 
Furthermore the so-called circulating fibrocyte precursor, a 
monocytic cell in the blood, is considered to be a potential 
precursor for fibroblasts. Interestingly monocytes of early 
SSc patients (and not of chronic SSc, RA and SLE patients) 
show an up regulation of the tumor necrosis factor convert-
ing enzyme (TACE) [39]. However, further phenotyping of 
CD14+ monocytes by flowcytometry in SSc patients with 
limited disease did not reveal differences in a number of the 
cell surface markers associated with activation, migration 
and transformation [40].  
 In summary, the phenotypic and functional analysis of 
monocytes in rheumatic diseases is elaborate and has re-
vealed a heterogeneous picture with inconsistent and some-
times contradictory results. Functional assays as described 
above are apparently not precise and robust enough to de-
termine the complex abnormalities of monocytes in rheu-
matic disease patients. The heterogeneity of rheumatic dis-
eases is another complicating factor. 
MONOCYTE GENE EXPRESSION PROFILING: A 
NOVEL APPROACH 
 Our recent studies show that by microarray analysis 
changes in gene expression profiles can be detected in 
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monocytes. A subsequent correlation of the data reveals 
functional pathways forming a specific “gene expression 
signature”, illustrating an abnormal pattern of monocyte ac-
tivation (an abnormal “set point”). These monocyte gene 
expression profiles and set points can be used for the study 
of large patient groups and the development of better classi-
fication criteria. It is important to note that in our experience, 
the more homogenous the patient groups and cell samples 
the clearer the results of such analysis.  
 Our microarray analysis were performed with CD14+ 
purified monocyte fractions because of the important role of 
monocytes and monocyte-derived cells in the pathogenesis 
of autoimmune diseases and the variability of the different 
cell types present in a PBMC fraction. Our profiling of 
CD14+ monocytes resulted in the identification of gene ex-
pression signatures for T1D, pSjS and autoimmune thyroidi-
tis [41, 42, Drexhage et al. unpublished results]. We detected 
two different signatures in T1D: a signature involving pri-
marily cytokine/inflammatory compound genes and a second 
signature that involves genes of chemotaxis, adhesion, motil-
ity and metabolism [42]. Interestingly, this latter gene ex-
pression signature is in line with our earlier observations on 
functional adhesion and chemotaxis abnormalities of mono-
cytes of T1D patients [43,44] underscoring the usefulness of 
gene profiling for unraveling functional pathways. Further-
more the existence of two different gene expression signa-
tures can clarify conflicting data reported on the pro-
inflammatory state of monocytes in T1D and the two de-
tected profiles provide a new method of classification of 
autoimmune diabetes. 
 For pSjS we used a similar approach resulting in the de-
tection of an IFN type I gene expression signature in mono-
cytes of patients [41]. Interestingly, the monocyte IFN type I 
signature is only present in a subgroup of patients with pSjS 
and correlates with disease activity (Brkic, unpublished re-
sults). Earlier observations on IFN type I activity in patients 
pointed towards a limited effect in the salivary glands since 
serum IFN type I could only be detected in a few patients 
[45-47]. Given a putative role for IFN type I in pSjS the next 
logical next step would be to treat these patients with inhibi-
tors of the IFN pathway using an anti-IFN type I monoclonal 
antibody or antibodies blocking the IFN type I receptor [48].  
 A subgroup of RA patients also displays the IFN expres-
sion signature in their monocytes (Versnel, unpublished re-
sults). This observation is consistent with data on PBMC 
profiling in RA [49]. Profiling of whole blood or peripheral 
blood mononuclear cells (PBMC) has been performed in 
rheumatic diseases in the assumption that PBMC gene ex-
pression profiles reflect the situation in the target tissues. 
This approach has also resulted in the identification of the 
IFN expression signature in peripheral blood mononuclear 
cells (PBMC) of patients with SLE, RA and SSc [49-51], 
despite the use of non- purified PBMC suspensions. For SLE 
the contribution of IFN type I in the pathogenesis of the dis-
ease had earlier been established using a variety of other 
approaches [48,52]. Although the use of PBMC thus suffices 
for the detection the IFN gene expression signature in rheu-
matic diseases, we favor the use of purified CD14+ mono-
cytes. The importance of the use of purified monocytes is 
supported by data from Batliwalla et al. [53] which shows 
that differences in monocyte counts between healthy controls 
and patients with RA influence the results obtained when 
profiling PBMC. Actually, most genes identified in this 
study were genes activated in monocytes. Moreover, in T1D 
it is essential to use monocytes, since the other cell popula-
tions contaminate and obscure the specific abnormal gene 
expression patterns found in the T1D monocytes. 
 The present concept on IFN type I in rheumatic diseases 
is that plasmacytoid DC secrete IFN type I in response to 
activation by e.g. immune complexes containing nucleic 
acids. Subsequently, this IFN type I activity results in an up 
regulation of a large number of IFN type 1 induced genes. In 
particular, the effect of IFN type I on monocytes seems to be 
important for the pathogenesis of rheumatic diseases since 
IFN type I induces monocytes to differentiate into DC and to 
express B cell–activating factor (BAFF). BAFF in turn con-
tributes to the survival and hyperactivity of autoreactive B 
cells, a hallmark of various rheumatic diseases [54]. 
CONCLUSION AND FUTURE DIRECTIONS 
 Rheumatic diseases are presently diagnosed by a combi-
nation of different tests that lack specificity for a single dis-
ease and vary within a disease group. Treatment of rheu-
matic diseases is frequently non-specific and not effective in 
all patients. Furthermore, the chronic nature with remissions 
and relapses in rheumatic diseases urges the identification of 
reliable biomarkers for disease activity.  
 Identification of monocyte gene expression signatures in 
larger patient samples will provide insight into the patho-
genesis of rheumatic diseases and provide tools for new clas-
sification methods. As the identified monocyte signatures are 
based on functional pathways involved in these diseases, 
new options for specific treatment of the various subgroups 
will become feasible. Furthermore, any such specific treat-
ment could possibly be monitored by using the monocyte 
signatures. We predict that in the future an accurate mono-
cyte profiling will precede and determine the treatment of a 
patient with a rheumatic disease.  
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